BCTX Stock Analysis: Buy, Sell, or Hold?
BCTX - Briacell Therapeutics Corp. Common Shares
$4.16
-0.16 (-3.71%)
▼
5d:
+0.12%
30d:
+11.99%
90d:
+34.03%
WAIT
LOW Confidence
Analysis Updated: Sep 28, 2026 12:00 AM ET
Earnings: Oct 21, 2026
21d
Get Alerted When BCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BCTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BCTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BCTX is currently trading at $4.16, which is considered extended relative to its 30-day fair value range of $3.54 to $4.10.
Technical Outlook: Technically, BCTX is in a uptrend. Immediate support is located at $3.48, while resistance sits at $4.43. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: BCTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $150.00 (+3510.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCTX is in a uptrend. Immediate support is located at $3.48, while resistance sits at $4.43. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: BCTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $150.00 (+3510.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.54 -
$4.10
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 3510.1% below Wall St target ($150.00)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.54 -
$4.10
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.48
Resistance Level
$4.43
Current Trend
Uptrend
Technical data as of
Sep 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.22
Wall Street Target
$150.00
(+3510.1%)
Share & Embed Analysis
Last updated: September 29, 2026 9:17 AM ET
Data refreshes hourly during market hours. Next update: 10:17 AM
Data refreshes hourly during market hours. Next update: 10:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 44 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 60 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 40 SELL |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$107 | 64 BUY |
